The National Medical Products Administration (NMPA) has issued a new set of “Guidelines for the Inspection of Third-Party Drug Online Trading Platforms,” signaling an upcoming wave of regulatory scrutiny for enterprises offering such services. The NMPA aims to enhance oversight through a targeted round of supervision and inspection.
The forthcoming routine inspections will prioritize three key areas: ① entities that are new to conducting third-party platform business, ② those operating third-party platforms without a professional background in drug distribution, and ③ third-party platforms with substantial operational scale, broad coverage, and significant business volume. The inspection methodologies will encompass both on-site and off-site approaches. On-site inspections involve in-person assessments by regulators at the business premises where the third-party platform services are provided. Off-site inspections, in contrast, will be conducted through various remote methods, including online patrols, network monitoring, and video calls.- Flcube.com
